Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Evogene Ltd
EVGN | US
0.80
USD-0.06
-6.90%
EVGN | US
About Evogene Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
0.80
Open
0.82
High
0.82
Low
0.78
Evogene Ltd. together with its subsidiaries operates as a computational biology company. It focuses on product discovery and development in life-science based industries including human health and agriculture through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture Human Health and Industrial Applications. The Agriculture segment develops seed traits ag-chemical products and ag-biological products to enhance plant performance. Its products focus on various crops such as corn soybean wheat rice and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology GI related disorders and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States Israel Brazil and internationally. The company has strategic collaborations and licensing agreements with agricultural companies such as BASF SE Corteva and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot Israel.
View LessEVGN | US
Risk
80.7
Sharpe
-0.23
Luna's Score
45/100
Recommendation
Sell
Luna says (EVGN | US)
What's Working
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
55.4%1 month
80.7%3 months
64.6%6 months
62.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.74
Debt to equity
0.26
Debt to assets
0.02
Ent. to EBITDA
-0.81
Ent. to rev.
0.39
PEG
-
Other Fundamentals
EBITDA
-19.67M
MarketCap
4.45M
MarketCap(USD)
4.45M
Div. yield
-
Op. margin
-667.07
Erngs. growth
-
Rev. growth
39.80
Ret. on equity
-82.37
Short ratio
0.63
Short perc.
0.27
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.11
Range1M
0.25
Range3M
0.52
Volumes: Market Activity
Rel. volume
0.35
Price X volume
32.17K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.81 | - | Cheaper |
| Ent. to Revenue | 0.39 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.74 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 64.58 | - | Par |
| Debt to Equity | 0.26 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 4.45M | - | Emerging |
